Zusammenfassung
Die Erdnussallergie ist eine potenziell lebensbedrohliche Erkrankung, da sie zu schweren allergischen Reaktionen, vor allem im Kindesalter, aber auch im Erwachsenenalter, führt. Bislang ist die Allergenkarenz die effektivste Therapie zur Behandlung einer Erdnussallergie. In der vorliegenden Arbeit werden aktuelle Entwicklungen zur kausalen Therapie einer Erdnussallergie anhand der vorhandenen Literatur kritisch diskutiert. Hierzu gehören die sublinguale, die epikutane und die orale Erdnussimmuntherapie. Auch unspezifische Behandlungsansätze mit zielgerichteten Antikörpern, wie dem Anti-IgE (Omalizumab) oder dem Anti-IL-4-IL-13-Rezeptor-Antikörper (Dupilumab) können in Hinblick auf den Wirkmechanismus zur Behandlung einer Erdnussallergie eingesetzt werden. Studien mit vielversprechenden Ergebnissen liegen für Omalizumab bereits vor und werden zukünftig für Dupilumab erwartet. Ob und welche Therapien zur Behandlung einer Erdnussallergie auf dem Markt verfügbar sein werden, ist nicht nur von der klinischen Wirksamkeit im Sinne einer langfristig stabilen Erhöhung der Schwellendosis relevant, sondern auch von der Verträglichkeit im Alltag der Betroffenen.
This is a preview of subscription content, log in via an institution to check access.
Change history
02 March 2022
Zitationshinweise im Seitenkopf wurden entfernt, da sie zu Verwirrung bei der Zitationsdatenbank von Clarivate geführt haben.
Referenzen
Worm M, Eckermann O, Dölle S, Aberer W, Beyer K, Hawranek T, et al. Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland. Dtsch Arztebl Int 2014;111:367-75
Bergmann KC, Heinrich J, Niemann H. Current status of allergy prevalence in Germany. Position paper of the Environmental Medicine Commission of the Robert Koch Institute. Allergo J Int 2016;25:6-10
Nwaru BI, Hickstein L, Panesar SS, Muraro A, Werfel T, Cardona V, et al. EAACI Food Allergy and Anaphylaxis Guidelines Group. The epidemiology of food allergy in Europe: a systematic review and meta-analysis. Allergy 2014;69:62-75
Grabenhenrich L, Trendelenburg V, Bellach J, Yürek S, Reich A, Fiandor A, et al. Frequency of food allergy in school-aged children in eight European countries-The EuroPrevall-iFAAM birth cohort. Allergy 2020;75:2294-308
Schoemaker AA, Sprikkelman AB, Grimshaw KE, Roberts G, Grabenhenrich L, Rosenfeld L, et al. Incidence and natural history of challenge-proven cow's milk allergy in European children - EuroPrevall birth cohort. Allergy 2015;70:963-72
Xepapadaki P, Fiocchi A, Grabenhenrich L, Roberts G, Grimshaw KEC, Fiandor A, et al. Incidence and natural history of hen's egg allergy in the first 2 years of life - the EuroPrevall birth cohort study. Allergy 2016;71:350-7
Peters RL, Allen KJ, Dharmage SC, Koplin JJ, Dang T, Tilbrook KP, et al. Natural history of peanut allergy and predictors of resolution in the first 4 years of life: A population-based assessment. J Allergy Clin Immunol 2015;135:1257-66
Maris I, Dölle S, Renaudin J-M, Lange L, Koehli A, Spindler T, et al. Peanut induced anaphylaxis in children and adolescents: data from the European Anaphylaxis Registry. Authorea 2020; https://doi.org/10.22541/au.159672620.00081079 (in Press)
Worm M, Reese I, Ballmer-Weber B, Beyer K, Bischoff SC, Classen M, et al. Guidelines on the management of IgE-mediated food allergies: S2k-Guidelines of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Medical Association of Allergologists (AeDA), the German Professional Association of Pediatricians (BVKJ), the German Allergy and Asthma Association (DAAB), German Dermatological Society (DDG), the German Society for Nutrition (DGE), the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS), the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery, the German Society for Pediatric and Adolescent Medicine (DGKJ), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Society for Pneumology (DGP), the German Society for Pediatric Gastroenterology and Nutrition (GPGE), German Contact Allergy Group (DKG), the Austrian Society for Allergology and Immunology (Æ-GAI), German Professional Association of Nutritional Sciences (VDOE) and the Association of the Scientific Medical Societies Germany (AWMF). Allergo J Int 2015;24:256-93
Kukkonen AK, Pelkonen AS, Mäkinen-Kiljunen S, Voutilainen H, Mäkelä MJ. Ara h 2 and Ara 6 are the best predictors of severe peanut allergy: a double-blind placebo-controlled study. Allergy 2015;70:1239-45
Krause S, Reese G, Randow S, Zennaro D, Quaratino D, Palazzo P, et al. Lipid transfer protein (Ara h 9) as a new peanut allergen relevant for a Mediterranean allergic population. J Allergy Clin Immunol 2009;124:771-8.e5
Schwager C, Kull S, Krause S, Schocker F, Petersen A, Becker WM, et al. Development of a novel strategy to isolate lipophilic allergens (oleosins) from peanuts. PLoS One 2015;10:e0123419
Mittag D, Akkerdaas J, Ballmer-Weber BK, Vogel L, Wensing M, Becker WM, et al. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy. J Allergy Clin Immunol 2004;114:1410-7
Cabanos C, Tandang-Silvas MR, Odijk V, Brostedt P, Tanaka A, Utsumi S, et al. Expression, purification, cross-reactivity and homology modeling of peanut profilin. Protein Expr Purif 2010;73:36-45
Pouessel G, Turner PJ, Worm M, Cardona V, Deschildre A, Beaudouin E, et al. Food-induced fatal anaphylaxis: From epidemiological data to general prevention strategies. Clin Exp Allergy 2018;48:1584-93
Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997;99:744-51
Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992;90:256-62
Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014;383:1297-304
Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral mmunotherapy: A randomized trial. J Allergy Clin Immunol 2015;135:737-44.e8
Bird JA, Spergel JM, Jones SM, Rachid R, Assa'ad AH, Wang J, et al. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. J Allergy Clin Immunol Pract 2018;6:476-85.e3
Vickery BP, Vereda A, Casale TB, Beyer K, Du Toit G, Hourihane JO, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med 2018;379:1991-2001
Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, et al. First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy. J Allergy Clin Immunol Pract 2019;7:2759-67.e5
Blümchen K, Trendelenburg V, Ahrens F, Gruebl A, Hamelmann E, Hansen G, et al. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy. J Allergy Clin Immunol Pract 2019;7:479-91.e10
Dupont C, Bourrier T, de Blay F, Guenard-Bilbault L, Sauvage C, Cousin MO,et al. Peanut Epicutaneous Immunotherapy (EPIT) in peanut-allergic children: 18 months treatment in the Arachild study. J Allergy Clin Immunol 2014;133:Ab102
Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Epicutaneous immunotherapy (EPIT) is effective and safe to treat peanut allergy: a multi-national double-blind placebo-controlled randomized phase IIb trial. J Allergy Clin Immunol 2015;135(2S):AB390
Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA 2017;318:1798-809
Sampson HA, Agbotounou W, Thébault C, Ruban C, Martin L, Sussman GL, et al. Enhanced efficacy and confirmed safety of a two-year epicutaneous immunotherapy (EPIT) treatment of peanut allergy with Viaskin peanut: the continuation of the Vipes phase IIb randomized controlled trial (RCT). J Allergy Clin Immunol 2016,137(2S):AB408
Jones SM, Agbotounou WK, Fleischer DM, Burks AW, Pesek RD, Harris MW, et al. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch. J Allergy Clin Immunol 2016;137:1258-61.e10
Jones SM, Sicherer SH, Burks AW, Leung DY, Lindblad RW, Dawson P, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol 2017;139:1242-52.e9
Fleischer DM, Greenhawt M, Sussman G, Bégin P, Nowak-Wegrzyn A, Petroni D, et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA 2019;12;321:946-55
Fleischer DM, Shreffler WG, Campbell DE, Green TD, Anvari S, Assa'ad A, et al. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results. J Allergy Clin Immunol 2020;146:863-74
Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011;127:640-6.e1
Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2013;131:119-27.e1-7
Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol 2015;135:1275-82.e1-6
Burks AW, Wood RA, Jones SM, Sicherer SH, Fleischer DM, Scurlock AM, et al. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol 2015;135:1240-8.e1-3
Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet 2019;393:2222-32
Yee CS, Rachid R. The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions. Curr Allergy Asthma Rep 2016;16:25
Nurmatov U, Dhami S, Arasi S, Pajno GB, Fernandez-Rivas M, Muraro A, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy 2017;72:1133-47
Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, Martín M. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. J Immunol Res 2016;2016:8163803
Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol 2016;16:751-65
Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004;59:973-9
Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003;348:986-93
MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017;139:873-881.e8.
Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, et al. A phase II, randomized, double blind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011;127:1309-10.e1
Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 2012 Nov;130:1123-9.e2
Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol 2018 Feb;3:85-94
Guttman-Yassky E, Bissonnette R, Ungar B, Suarez-Fari M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019;143:155-72
Chinthrajah S, Cao S, Liu C, Lyu SC, Sindher SB, Long A, et al. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI Insight 2019;4:e131347
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
M. Worm berichtet über Honorare für Advisory Boards und Vortragsaktivitäten von Regeneron Pharmaceuticals, DBV Technologies SA, Stallergenes GmbH, HAL Allergie, Bencard Allergie, Allergopharma, ALK-Abelló Arzneimittel, Mylan Germany, Leo Pharma , Sanofi-Aventis Deutschland, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland, Novartis, Biotest, AbbVie Deutschland, Lilly Deutschland - außerhalb der eingereichten Arbeit.
Die übrigen Autoren geben an, dass keine Interessenkonflikte bestehen.
Rights and permissions
About this article
Cite this article
Worm, M., Francuzik, W., Dölle, S. et al. Aktuelle Entwicklungen zur Therapie der Erdnussallergie. Allergo J 30, 30–39 (2021). https://doi.org/10.1007/s15007-021-4774-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15007-021-4774-0